273 related articles for article (PubMed ID: 24465210)
1. Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals.
Pickering S; Hué S; Kim EY; Reddy S; Wolinsky SM; Neil SJ
PLoS Pathog; 2014 Jan; 10(1):e1003895. PubMed ID: 24465210
[TBL] [Abstract][Full Text] [Related]
2. Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes.
Umviligihozo G; Cobarrubias KD; Chandrarathna S; Jin SW; Reddy N; Byakwaga H; Muzoora C; Bwana MB; Lee GQ; Hunt PW; Martin JN; Brumme CJ; Bangsberg DR; Karita E; Allen S; Hunter E; Ndung'u T; Brumme ZL; Brockman MA
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376625
[TBL] [Abstract][Full Text] [Related]
3. Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.
Jafari M; Guatelli J; Lewinski MK
J Virol; 2014 May; 88(9):5062-78. PubMed ID: 24574397
[TBL] [Abstract][Full Text] [Related]
4. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
Vigan R; Neil SJ
J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
[TBL] [Abstract][Full Text] [Related]
5. The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.
Waheed AA; Swiderski M; Khan A; Gitzen A; Majadly A; Freed EO
J Biol Chem; 2020 May; 295(21):7327-7340. PubMed ID: 32291285
[TBL] [Abstract][Full Text] [Related]
6. Modest attenuation of HIV-1 Vpu alleles derived from elite controller plasma.
Chen J; Tibroni N; Sauter D; Galaski J; Miura T; Alter G; Mueller B; Haller C; Walker BD; Kirchhoff F; Brumme ZL; Ueno T; Fackler OT
PLoS One; 2015; 10(3):e0120434. PubMed ID: 25793728
[TBL] [Abstract][Full Text] [Related]
7. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
8. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
[TBL] [Abstract][Full Text] [Related]
9. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
10. Functional conservation and coherence of HIV-1 subtype A Vpu alleles.
Romani B; Kavyanifard A; Allahbakhshi E
Sci Rep; 2017 Dec; 7(1):87. PubMed ID: 28273896
[TBL] [Abstract][Full Text] [Related]
11. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
[TBL] [Abstract][Full Text] [Related]
12. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
[TBL] [Abstract][Full Text] [Related]
13. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
14. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
15. Human-Specific Adaptations in Vpu Conferring Anti-tetherin Activity Are Critical for Efficient Early HIV-1 Replication In Vivo.
Yamada E; Nakaoka S; Klein L; Reith E; Langer S; Hopfensperger K; Iwami S; Schreiber G; Kirchhoff F; Koyanagi Y; Sauter D; Sato K
Cell Host Microbe; 2018 Jan; 23(1):110-120.e7. PubMed ID: 29324226
[TBL] [Abstract][Full Text] [Related]
16. Modulation of HIV-1-host interaction: role of the Vpu accessory protein.
Dubé M; Bego MG; Paquay C; Cohen ÉA
Retrovirology; 2010 Dec; 7():114. PubMed ID: 21176220
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses.
Prévost J; Pickering S; Mumby MJ; Medjahed H; Gendron-Lepage G; Delgado GG; Dirk BS; Dikeakos JD; Stürzel CM; Sauter D; Kirchhoff F; Bibollet-Ruche F; Hahn BH; Dubé M; Kaufmann DE; Neil SJD; Finzi A; Richard J
mBio; 2019 Jun; 10(3):. PubMed ID: 31213558
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
19. Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.
Mack K; Starz K; Sauter D; Langer S; Bibollet-Ruche F; Learn GH; Stürzel CM; Leoz M; Plantier JC; Geyer M; Hahn BH; Kirchhoff F
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077643
[TBL] [Abstract][Full Text] [Related]
20. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
Lucas TM; Janaka SK; Stephens EB; Johnson MC
PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
